The United Kingdom and the United States have concluded a major trade agreement that will keep zero import taxes on British medicine products being sold in the American market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has pledged to boost funding on drugs through the public health system. This pledge secures that duties on these vital goods will remain at zero for a duration of the next three years.
This development is in response to earlier statements to hike duties on branded pharmaceutical imports, with increases discussed as high as double the cost.
"This arrangement with the UK bolsters the worldwide climate for innovative medicines and establishes long-overdue balance to U.S.–U.K. drug exports," a release noted.
Trade Significance
Medicines are one of the Britain's biggest export categories to the United States, which is clearly the biggest destination for leading British pharmaceutical firms.
Export figures indicate that in the year to the end of September, the UK shipped pharmaceutical products worth billions to the US. This value represented a significant portion of total UK exports in that timeframe.
"This agreement secures jobs, boosts investment and facilitates the UK to become a international leader for life sciences," a government official commented.
Key UK Commitments
The deal entails several specific pledges from the UK:
- Higher Cost Ceiling: The UK will lift the cost ceiling at which it considers new treatments to be unaffordable by twenty-five percent.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on medicines from 0.3 percent of GDP to 0.6 percent over the next decade.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. Previously, rebates topped 20%.
Industry Background
The pact takes place against a ongoing row between the drug companies and the ministers over drug pricing and approval rates.
This friction were exacerbated by arguments that US consumers were charged several times more for the identical medicines than consumers in the other developed nations.
Over the last 18 months, several significant pharmaceutical investments in the UK have been halted or scrapped, while substantial investments have been pledged toward American operations.
A senior figure stated that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had decreased as a proportion of its overall budget over the previous ten-year period.
